Additional implications of these results are significant because most men who receive androgen-deprivation therapy are neither evaluated nor treated for bone loss.44, 45 The ETAR antagonists bosentan and ambrisentan are currently approved for treatment of advanced pulmonary hypertension,46, 47 but the impact of these medications in this population is unknown. This evidence concerns the gene EDNRA and pulmonary arterial hypertension.